Table 1 Patient characteristics

Age

49.0 ± 13.6

60.0 ± 13.3

62.9 ± 12.7

0.021

Male, n (%)

6 (60)

25 (75.8)

20 (58.8)

0.348

BMI

23.4 ± 4.0

24.8 ± 4.3

29.7 ± 4.7

0.001

Current Smoker, n (%)

2 (20.0)

10 (30.3)

12 (35.3)

0.653

 FEV₁/FVC

71.9 ± 13.2

73.2 ± 18.9

79.1 ± 13.9

0.078

 FEV₁, Litre

2.12 ± 0.44

1.75 ± 0.82

1.91 ± 0.80

0.400

 FEV₁ (% predicted)

68.6 ± 15.9

65.3 ± 24.6

77.1 ± 25.3

0.132

 FVC, Litre

2.94 ± 0.42

2.39 ± 0.83

2.41 ± 0.84

0.096

Decline of FEV₁/year, (% from baseline)

1.3 ± 1.3

3.1 ± 3.3

4.3 ± 3.4

0.024

Decline of FEV₁/year, (% predicted)

0.0 ± 1.1

1.0 ± 1.9

2.3 ± 3.0

0.027

Decline of FEV₁/year (mL)

24.3 ± 27.5

41.9 ± 45.3

72.4 ± 61.7

0.046

Decline of FVC/year, (% from baseline)

1.1 ± 3.6

1.4 ± 3.4

2.6 ± 3.6

0.499

Decline of FVC/year, (% predicted)

0.6 ± 3.4

0.8 ± 2.6

1.6 ± 2.9

0.608

Decline of FVC/year, (mL)

32.5 ± 111.1

39.9 ± 84.4

54.9 ± 76.1

0.735

ER visit, n/year

0.11 ± 0.14

0.48 ± 0.63

0.52 ± 0.62

0.256

 Inhaled glucocorticoid

9 (90)

33 (100)

31 (91.2)

0.208

 Inhaled long-acting beta-agonist

6 (60)

25 (75.8)

30 (88.2)

0.128

 Leukotriene antagonist

1 (10)

10 (30.3)

21 (61.8)

0.003